Aligos Therapeutics, Inc.

ALGSSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1799448

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$3.6M	$6.2M	$6.2M	$0.00	$0.00
Research and Development Expense	$70.3M	$73.0M	$85.1M	$104.2M	$79.9M
Operating Expenses	$93.1M	$103.7M	$111.5M	$132.7M	$97.8M
Operating Income (Loss)	-$89.2M	-$88.1M	-$97.6M	-$128.3M	-$97.8M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$130.9M	-$86.9M	-$95.9M	-$128.2M	-$108.4M
Income Tax Expense (Benefit)	$331.0K	$795.0K	$106.0K	$143.0K	$161.0K
Net Income (Loss) Attributable to Parent	-$131.2M	-$87.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$70.1M	$151.5M	$146.7M	$235.4M	$265.3M
Assets, Current	$62.1M	$141.1M	$133.5M	$204.4M	$250.0M
Cash and Cash Equivalents, at Carrying Value	$37.0M	$135.7M	$81.3M	$186.8M	$220.4M
Liabilities	$99.1M	$59.4M	$42.8M	$50.6M	$45.3M
Liabilities, Current	$21.7M	$23.9M	$33.1M	$39.0M	$30.3M
Accounts Payable, Current	$2.6M	$2.5M	$4.7M	$3.0M	$3.3M
Stockholders' Equity Attributable to Parent	$92.1M	$103.9M	$184.7M	$220.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$80.7M	-$79.0M	-$79.4M	-$115.7M	-$74.3M
Net Cash Provided by (Used in) Investing Activities	-$18.3M	$45.0M	-$26.3M	$3.0M	$32.8M
Net Cash Provided by (Used in) Financing Activities	$355.0K	$88.3M	$164.0K	$78.7M	$192.3M
Payments to Acquire Property, Plant, and Equipment	—	$19.0K	$943.0K	$892.0K	$2.1M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)